°ñ´Ù°øÁõ ±Ç°í ¿ä¾àº»
- ÀúÀÚ(±Û)Á¤È£¿¬
- ÃâÆÇ»çÀ̹®±â¾÷
- ¹ßÇàÀÏ2024
°ñ´Ù°øÁõ Áø·áÀÇ ¿À·£ °æÇè
| Á¦ ¸ñ | ±Ù°¨¼ÒÁõ |
|---|---|
| ÃâÆÇ»ç | ±ºÀÚÃâÆÇ»ç |
| ¹ßÇàÀÏ | 2017 |
| Á¦ ¸ñ | °ñ´Ù°øÁõ |
|---|---|
| ÃâÆÇ»ç | 2016 |
| ¹ßÇàÀÏ | ±ºÀÚÃâÆÇ»ç |
| Á¦ ¸ñ | °ñ´Ù°øÁõ |
|---|---|
| ÃâÆÇ»ç | 2013 |
| ¹ßÇàÀÏ | ±ºÀÚÃâÆÇ»ç |
| Á¦ ¸ñ | ³»ºÐºñ´ë»çÇÐ |
|---|---|
| ÃâÆÇ»ç | 2022 |
| ¹ßÇàÀÏ | ±ºÀÚÃâÆÇ»ç |
| Á¦ ¸ñ | ³»ºÐºñ´ë»çÇÐ |
|---|---|
| ÃâÆÇ»ç | 2011 |
| ¹ßÇàÀÏ | ±ºÀÚÃâÆÇ»ç |
| Á¦ ¸ñ | °ñ´Ù°øÁõ Áø·áÁöħ 2024 |
|---|---|
| ÃâÆÇ»ç | 2024 |
| ¹ßÇàÀÏ | ´ëÇѰñ´ë»çÇÐȸ |
| Á¦ ¸ñ | Position statement: postmenopausal osteoporosis treatment strategies in Korea |
|---|---|
| ¹ßÇ¥³âµµ | 2023 |
| ¹ßÇ¥Áö | JBM |
| Á¦ ¸ñ | Effect of bazedoxifene/vitamin D combination therapy on serum vitamin D levels and BTM in postmenopausal women with osteopenia |
|---|---|
| ¹ßÇ¥³âµµ | 2023 |
| ¹ßÇ¥Áö | JBM |
| Á¦ ¸ñ | Denosumab-induced hypocalcemia in a patient with hyperthyroidism |
|---|---|
| ¹ßÇ¥³âµµ | 2022 |
| ¹ßÇ¥Áö | Osteoporos Int |
| Á¦ ¸ñ | Delayed diagnosis of pseudohypoparthyroidism type1a with rare hypothyroidism since childhood |
|---|---|
| ¹ßÇ¥³âµµ | 2022 |
| ¹ßÇ¥Áö | Oxford Med Case Rep |
| Á¦ ¸ñ | Raloxifene/vitamin D combination therapy vs. Raloxifene monotherapy on serum 25OHD level among PMO or osteopenia |
|---|---|
| ¹ßÇ¥³âµµ | 2022 |
| ¹ßÇ¥Áö | JBM |
| Á¦ ¸ñ | Effect of AGE products on differentiation and function of osteoblasts and osteoclasts |
|---|---|
| ¹ßÇ¥³âµµ | 2021 |
| ¹ßÇ¥Áö | JKMS |
| Á¦ ¸ñ | Incidence of subsequent osteoporotic fractures after distal radius fractures and mortality of subsequent distal radius fractrues |
|---|---|
| ¹ßÇ¥³âµµ | 2021 |
| ¹ßÇ¥Áö | Osteoporos Int |
°ñ´Ù°øÁõÀÇ Áø·á¿¡¼ °¡Àå ÃÖ½ÅÀÇ Ä¡·á¸¦, ±×¸®°í Ç¥ÁØÈµÈ Ä¡·á¸¦ ³Î¸® ¾Ë¸®´Â °ÍÀÌ Áß¿äÇÏ´Ù´Â Á¡¿¡¼ ÇÐȸ¿¡¼ ÁÖ±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ® µÇ´Â Áø·áÁöħ¼ÀÇ ¹ß°£¿¡ Áö¼ÓÀûÀ¸·Î Âü¿©ÇÔ
¸ðµç ȯÀÚ°¡ ¶È°°Áö ¾Ê±â ¶§¹®¿¡ °¡Àå ȯÀÚ¿¡°Ô ÀûÀýÇϰí ÇÊ¿äÇÑ Áø·á ³»¿ëÀÌ ¹«¾ùÀΰ¡¸¦ ã¾Æ³»°í ¶ÇÇÑ °¡Àå À̵æÀÌ µÇ´Â Ä¡·á¸¦ À§ÇØ ³ë·ÂÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù.
¸¸¼ºÀûÀÎ ÁúȯÀ¸·Î Áõ»óÀÌ ¾øÁö¸¸ Ä¡¸íÀûÀÎ °á°ú¸¦ º¸ÀÏ ¼ö ÀÖ´Â Áúº´ÀÎ ¸¸Å Áö¼ÓÀûÀÎ °ü½É°ú ³ë·ÂÀÌ ÇÊ¿äÇÏ°í ³ë·ÂÇÑ ¸¸Å »óÀÀÇÏ´Â À̵æÀÌ ÀÖÀ» ¼ö ÀÖ´Ù´Â »ý°¢ÀÌ ÇÊ¿äÇÔ

°µ¿°æÈñ´ëÇб³º´¿øÀº Àǰú, ÇÑÀǰú, Ä¡°ú´ëÇÐÀ» ¸ðµÎ º¸À¯ÇÑ º´¿øÀ¸·Î, 3°³ ´ëÇк´¿øÀÇ ¼öÁØ ³ôÀº ÀǷἺñ½º¸¦ ÇÑ ¹ø¿¡ ¹ÞÀ» ¼ö ÀÖ´Ù. ¿¬¸éÀû 24,000¿© Æò º»°ü Áö»ó 14Ãþ, º°°ü Áö»ó 4ÃþÀÇ 800º´»óÀ» °®Ãè´Ù. ³úÁúȯ¡¤°üÀý¡¤Ã´Ãß µî Áúȯ Áß½ÉÀ¸·Î Æ¯ÈµÈ ÇùÁø ÀÇ·á
¼ºñ½º¸¦ Á¦°øÇÏ´Â ÀÇ¡¤ÇÑ ÇùÁø¼¾ÅÍ, ȯÀÚ ¼¼°è ÃÖ°í ¼öÁØÀÇ Áø·á½Ã½ºÅÛÀ» °®Ãá Àǰú
´ëÇк´¿ø, ÇÑÀÇÇÐÀ» ¼±µµÇÏ´Â ÇÑ¹æ ºê·£µåÆÄÀ§ 1À§ ÇÑÀǰú´ëÇк´¿ø¿Í Àü¹®¼º°ú ÆíÀǼºÀ» °®Ãá ȯÀÚ¸¸Á· º´¿øÀÎ Ä¡°ú´ëÇк´¿øÀÌ ÃÖ»óÀÇ ÀǷἺñ½º¸¦ Á¦°øÇϰí ÀÖ´Ù.
¼¿ïƯº°½Ã °µ¿±¸ µ¿³²·Î 892